Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report

Table 1 Literature review of pediatric patients with vincristine induced vocal cord palsy

Authors	Sex/age	Diagnosis	Duration, weeks	Vocal cord palsy	Airway intervention	Swallowing dysfunction	Associated neuropathy	Subsequent vincristine administration
Tobias and Bozeman [2]	M/5 years	ALL	0.5	L	No	No	No	Omitted
Tobias and Bozeman [2]	F/2 years	NHL-T	2	L	No	No	Yes	Half dose
Annino et al. [3]	M/1.5 years	RMS	6	BL	No	Yes	No	Omitted
	M/1.3 years	Ependymoma	2	BL	No	No	No	Omitted
	M/3 years	ALL	2	L	No	No	Yes	Half dose
Agarwall et al. [4]	F/11 years	LNH	NA	R	No	No	No	NA
Anghelescu et al. [5]	NA/0.4 years	ALL	1	BL	Yes	Yes	No	NA
Graf et al. [6]	M/15 years	ALL + CMT	34.3	BL	No	No	Yes	NA
Ahmad et al. [7]	M/3 years	ALL + Down’s	38.5	BL	Yes	Yes	No	Omitted
	M/1.8 years	Ependymoma	34.3	BL	No	No	No	Omitted
	M/2 years	ALL	27	BL	No	Yes	Yes	Omitted*
Kuruvilla et al. [1]	F/1 year	ALL	37	BL	Yes	Yes	No	Omitted
	M/4 years	ALL + Down’s	20	BL	Yes	No	Yes	Half dose
	M/5 years	ES	7	BL	No	No	No	No indication
	M/3 years	RMS	4	L	No	Yes		Half dose, then increased to regular regimen
Latiff et al. [8]	M/2 years	ALL	13	BL	No	No	No	Half dose**
Latiff et al. [8]	F/3 years	ALL	40	BL	Yes***	No	No	Half dose
Naithani et al. [9]	M/14 years	ALL	6	BL	No	Yes	Yes	Omitted

*Vincristine definitely omitted after symptoms recurrence in consequence of drug reintroduction at full dose (drug initially given at 25% of recommended dose and gradually increased to full dose)
**Vincristine definitely omitted after symptoms recurrence in consequence of drug reintroduction at half dose
***Cordectomy.
ALL = acute lymphoblastic leukemia; BL = bilateral; CMT = Charcot Marie Tooth; Down’s = Down’s syndrome; ES = Ewing’s sarcoma; L = left; NA = not assessed; NHL-T = T cell non-Hodgkin’s lymphoma; R = right; RMS = rhabdomyosarcoma